Saccharomyces cerevisiae CNCM I-1077
Saccharomyces cerevisiae CNCM I-1077 is a specific probiotic yeast strain currently studied only in veterinary applications for digestive health support. This strain contains beta-glucans and mannanoligosaccharides that may improve microbial colonization in animal digestive systems.
Origin & History
Saccharomyces cerevisiae CNCM I-1077 is a specific strain of yeast deposited at the Collection Nationale de Cultures de Microorganismes (CNCM), primarily used as a probiotic feed additive under the trade name LEVUCELL® SC. It is produced via fermentation and drying processes, yielding viable cells that are biochemically characterized using API 20C gallery and identified via PCR methods.
Historical & Cultural Context
No historical or traditional medicine use is documented for Saccharomyces cerevisiae CNCM I-1077, as it is a modern industrial strain selected specifically for veterinary probiotic applications. Unlike other S. cerevisiae strains such as S. boulardii which have probiotic history, this strain has no traditional use in human health.
Health Benefits
• Currently no documented human health benefits - this strain is only studied in veterinary applications • May support digestive health in animals through improved rumen microbial colonization (animal studies only) • Related S. cerevisiae strains show anti-inflammatory effects in animal colitis models (different strain, not CNCM I-1077) • No human clinical trials or systematic reviews available for this specific strain • Evidence limited to veterinary feed applications without human health data
How It Works
CNCM I-1077 contains beta-glucans in its cell wall that may stimulate immune responses through Toll-like receptor activation. The strain's mannanoligosaccharides potentially act as prebiotics, promoting beneficial bacterial growth in the digestive tract. Related S. cerevisiae strains modulate inflammatory pathways by reducing NF-kappaB activation and cytokine production.
Scientific Research
No human clinical trials, RCTs, or meta-analyses are available for Saccharomyces cerevisiae CNCM I-1077. The strain has been studied exclusively in veterinary contexts, particularly for improving rumen microbial colonization in calves. A different S. cerevisiae strain (SC28-7) showed anti-inflammatory effects in mouse colitis models, but this research does not apply to CNCM I-1077.
Clinical Summary
Currently, no human clinical studies exist for Saccharomyces cerevisiae CNCM I-1077, with research limited exclusively to veterinary applications. Animal studies in ruminants suggest improved digestive microbial balance, but specific study details including sample sizes and quantified outcomes are not well-documented in peer-reviewed literature. Related S. cerevisiae strains have shown anti-inflammatory effects in animal colitis models, but this specific strain lacks human safety and efficacy data. The evidence base remains insufficient for human supplementation recommendations.
Nutritional Profile
Saccharomyces cerevisiae CNCM I-1077 is a single-celled fungal organism; as a probiotic/fermentation ingredient, it contributes minimal macronutrient load at typical dosing levels (product-dependent, often 1–10 billion CFU/dose). General S. cerevisiae compositional data (per 100g dry cell mass, extrapolated from well-characterized strains): Protein: 40–50g (rich in glutamic acid, aspartic acid, leucine; contains all essential amino acids); Carbohydrates: 35–45g (primarily cell wall beta-1,3/1,6-glucans ~25–30g and mannan/mannoproteins ~15–20g); Lipids: 2–5g (predominantly unsaturated fatty acids, oleic and linoleic acid). Micronutrients (per 100g dry weight, strain-specific data unavailable, based on S. cerevisiae class): B-vitamins notably thiamine (B1): ~10–15mg, riboflavin (B2): ~4–6mg, niacin (B3): ~35–50mg, pantothenic acid (B5): ~10–15mg, pyridoxine (B6): ~3–5mg, folate: ~2–3mg; Minerals: zinc ~7–10mg, selenium variable (substrate-dependent, typically 0.1–0.3mg), phosphorus ~1.5–2g (predominantly as phytic acid, reducing bioavailability), potassium ~1.5–2g, magnesium ~200–300mg. Bioactive compounds: beta-glucans (immunomodulatory, cell wall-derived); mannooligosaccharides (MOS, prebiotic potential in gut/rumen); ergosterol (provitamin D2 precursor, ~5–10mg/100g dry weight, bioavailability enhanced by UV exposure). Bioavailability notes: At probiotic dose levels (mg range), macronutrient and micronutrient contributions to human dietary intake are negligible (<1% RDI). Beta-glucans and MOS are the primary functionally relevant compounds at physiological concentrations. Phytate content limits mineral bioavailability from whole-cell preparations. CNCM I-1077 strain-specific compositional data is not publicly documented in peer-reviewed literature; figures above represent S. cerevisiae species-level estimates.
Preparation & Dosage
No clinically studied human dosages are available. In veterinary applications, LEVUCELL® SC20 provides ≥20 × 10⁹ CFU/g viable cells (uncoated powder) and LEVUCELL® SC10ME provides ≥10 × 10⁹ CFU/g (coated powder). Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Not applicable - no human use data available
Safety & Interactions
Safety data for human consumption of CNCM I-1077 is unavailable since studies focus only on veterinary use. General S. cerevisiae supplementation may cause bloating, gas, or digestive discomfort in sensitive individuals. Individuals with compromised immune systems or central venous catheters should avoid yeast-based probiotics due to potential systemic infection risk. No specific drug interactions or pregnancy safety data exists for this particular strain.